BACKGROUND: Promoter hypermethylation is an important epigenetic mechanism in the regulation of several key modulators of prostate carcinoma progression. Recent studies suggest that the polycomb-group (PcG) protein BMI1 may have an impact on epigenetic regulation of several targets, including the CDKN2a locus.
Introduction
Prostate cancer (PCa) is the third most frequent human tumour worldwide; its incidence is especially high in Western Europe and the United States, and low in Asian countries. The overall prognosis is good, with a 5-year survival rate of about 70%. 1 Currently, the established prognostic factors for prostatic carcinoma recommended for routine reporting are TNM stage, surgical margin status, serum PSA and Gleason score. 2, 3 Tumour prognosis worsens with increasing Gleason grade and score. Gleason score 7 tumours are heterogeneous with a more aggressive behaviour in carcinomas that are Gleason 7b ¼ 4 þ 3 compared with Gleason 7a ¼ 3 þ 4. 3, 4 Although recent advances in the study of proteomics and highthroughput techniques have discovered many potential biomarkers for PCa, [5] [6] [7] there still remains a need for biomarkers to predict the outcomes of the tumour. [8] [9] [10] Therefore, we focused on epigenetic events such as aberrant promoter methylation to identify new markers predicting PCa aggressiveness.
Genes frequently modulated by DNA methylation in PCa include those involved in cell cycle control, apoptosis, DNA repair or metastasis, such as GSTP1, RASSF1A and APC. [11] [12] [13] [14] [15] The polycomb group (PcG) of proteins BMI1, EZH2, and SIRT1 are characteristic components of the polycomb repression complex 1, 2 and 4, respectively, that modify chromatin. Recent studies suggested a direct influence of increased polycomb proteins on altered DNA-methylation patterns and hence gene silencing in prostate cancer. 16, 17 Several reports have shown that a BMI1-driven pathway is involved in several human cancers, including prostate carcinoma, and has a major role in tumour progression. [17] [18] [19] Two such putative targets of this BMI1-mediated epigenetic regulation and gene repression are promoters of two alternate splice variants of CDKNa locus, namely, promoters for p16 INK4a , and p14 ARF and TMS1. [20] [21] [22] [23] [24] [25] [26] [27] However, investigation of BMI1-associated epigenetic regulation of CDKN2a and TMS1 to predict aggressiveness of PCa has remained unattempted. Therefore, we investigated the role of BMI1 expression and promoter methylation of CDKN2a and TMS1 and analysed their association with histological markers of aggressiveness such as Gleason score, extraprostatic tumour extension, tumour size and perineural invasion in prostatectomy specimens.
Materials and methods

Patient samples from the archive
A series of 91 formalin-fixed paraffin-embedded prostatectomy specimens with primary prostate adenocarcinoma (PCa) from the archive of the Institute for Pathology, Ruhr-University of Bochum, between 2006 and 2007 were collected for the study. The composition of the cohort concerning pT category, status of lymph nodes and Gleason score is shown in Table 1 . The PCa specimens were subjected to histological examination by an expert pathologist for confirmation of the Gleason grades, WHO classification of tumours and staging according to the TNM system. Subsequently, the histopathological tumour regions of interest were microdissected as described below and used for DNA extraction. The study has been approved by the local ethics committee in accordance with the principles outlined in the Declaration of Helsinki.
DNA isolation and sodium bisulphite modification
Sections of size 10 mm were cut from archived formalinfixed paraffin-embedded tissue. After heating for 1 h at 62 1C, slides were deparaffinized and rehydrated by passing them through xylene and then through a graded isopropanol series. Tumour tissue was manually microdissected from 5-8 10-mm sections using a scalpel, with the corresponding HE slide as a guide (tumour was marked with a pen on the HE slide). This method is suitable as promoter hypermethylation of our genes of interest is not expected in the tumour stroma. 11, 28 DNA isolation was performed using the Qiagen FFPEtissue kit (Qiagen, Hilden, Germany) following the instructions of the manufacturer. One mg of genomic DNA was subjected to bisulphite conversion using the EZ-Methylation kit (ZYMO Research, Orange, CA, USA).
Methylation-sensitive PCR
Methylation-sensitive PCR amplification of p16
INK4a , p14 ARF and TMS1 was performed in a 20-ml reaction volume with 1 ml (50 ng) of bisulphite-treated DNA using TrueStart Taq (Fermentas, St Leon-Rot, Germany) using previously reported primers. [28] [29] [30] The primer sequences and conditions are summarized in Supplementary Table 1 . Each PCR was loaded to an 8% polyacrylamide gel, stained with ethidium bromide and visualized under ultraviolet illumination.
Immunohistochemistry
Three-mm sections of paraffin-embedded specimens were cut, deparaffinized with xylene and rehydrated through a graded alcohol series. Antigen retrieval was carried out with Target Retrieval Solution pH 9.0 (DAKO, Hamburg, Germany) at 95 1C in a water bath for 30 min. The sections were then treated with 3% hydrogen peroxide in methanol for 10 min to quench the endogenous peroxidase activity, followed by incubation with 2% bovine serum albumin to block the nonspecific binding. The specimens were incubated overnight at 4 1C with anti-BMI1 (Clone F6, Millipore, Schwalbach, Germany, 1:750 dilution). Sections were stained in a DAKO autostainer (DAKO), using the Vectastain elite universal kit (Vector, Burlingame, CA, USA), with 3,3 0 -diaminobenzidine as the substrate, and counterstained with hematoxylin. Expression was quantified as percentage of nuclei with stronger total staining intensity than benign glands from the same slide.
Statistical analysis
All statistical analyses were carried out with the Statistica version 9 software package (Statsoft, Hamburg, Germany). Significance testing with continuous variables was performed using the Mann-Whitney U-test (for comparison of two groups) or Kruskal-Wallis test (for comparison of more than two groups). In case of ordinal variables, the w 2 -test was used (when all combinations had at least five cases); if not, Fisher's exact test was applied.
Results
BMI1 overexpression in prostate carcinoma of higher Gleason score and extraprostatic tumour extension
Expression and subcellular localization of BMI1 protein were determined by immunohistochemistry in 70 paraffin-embedded prostate carcinoma samples of varying Gleason score and in adjacent benign prostate tissues (Figures 1 and 2) . In tumour tissue, specific BMI1 signals were localized mainly in the nuclei of carcinoma cells. BMI1 expression was detectable in all samples in the study population. However, the majority of prostate tumour sections showed cells overexpressing BMI1 in Figure 1a ). The median of BMI1-overexpressing cells in prostate tumour sections was 11.8% (range 0-87%), but only 10% of samples had less than 5% BMI1-negative cells. These typically represented Gleason score 3 þ 3 and 3 þ 4. PCa with Gleason score X8 exhibited a median of 21.7% BMI1-overexpressing cells, and those with Gleason score 4 þ 3 exhibited a median of 23.7% BMI1-overexpressing cells. In contrast, tumours with Gleason score 3 þ 3 and 3 þ 4 exhibited a median of only 5.7% and 11.9% BMI1-overexpressing cells, respectively. Although tumours with higher Gleason score revealed more BMI1 expression, no statistical significance was observed (P ¼ 0.184) (Figure 2 ).
In addition, PCa with extraprostatic extension (pT3) exhibited a median of 14.4% BMI1-overexpressing cells, in contrast to a median of 7% BMI1-overexpressing cells in tumours confined to the prostate (pT2) (Figure 2) . Furthermore, tumours with perineural invasion (PCaPn1) and without perineural invasion (PCa-Pn0) were analysed for BMI1 expression. Pn1-PCa exhibited a median of 14.4% BMI1-overexpressing cells in contrast to a median of 5.9% BMI1 positive cells Pn0-PCa.
Our results showed a higher percentage of BMI1 overexpressing cells in prostate carcinoma with Gleason score 7b ¼ 4 þ 3 and X8, extraprostatic tumour extension, and perineural invasion, however, no statistical significance was observed. No association of BMI1 expression with age of the patients or tumour size was observed.
Promoter methylation of p16
INK4a shows inverse association with Gleason score as compared with methylation of p14
ARF
We investigated the promoter methylation status of CDKN2a and TMS1 in PCa cells with different Gleason scores using methylation specific PCR (Figure 3 , p14 ARF and TMS1 promoter methylation and perineural invasion, the frequency of p16 INK4a , p14 ARF and TMS1-promoter methylation in PCa-Pn1 and PCaPn0 was evaluated. Pn1-PCa represented 60.4% (55 of 91) of the investigated PCa study population. We observed that p16 INK4a (P ¼ 0.040) and TMS1 (P ¼ 0.242) promoter methylation was more frequent in Pn1-PCa than in Pn0-Pca, whereas p14 ARF methylation exhibited no discernible differences between both categories (P ¼ 0.861). These observations were consistent but not significant with the relation between p16
Methylation of
INK4a -methylation and T category (as most pT3 cases are also Pn1-PCa). In this patient group, no cases had (known) distant metastases at the time of diagnosis and only three patients had lymph node metastases, and hence no meaningful statistical analysis could be performed to evaluate the relationship between promoter methylation and metastases. The evaluation of methylation of all three investigated gene promoters with age revealed no significant correlations.
BMI expression and methylation of p16
INK4a and p14 ARF Next, we analysed for the relation between BMI1 expression and promoter methylation of all three investigated gene promoters. We observed no significant changes for BMI1-over-expressing cells and 16 INK4a promoter methylation (P ¼ 0.556), TMS1 methylation (P ¼ 0.707) or p14 ARF methylation (P ¼ 0.335) (Figure 4 ).
Discussion
DNA methylation of gene promoters causes gene silencing and is a common event in cancer development and progression. Evaluation of aberrant promoter methylation is accepted as a diagnostic and prognostic Methylation of p 16INK4a and p14 ARF in prostate cancer B Verdoodt et al marker for many cancers, including PCa. 8, 31 Previous studies have suggested that in stem cells, polycomb target genes (PcG) are predisposed to DNA hypermethylation through global histone modification, and thus may have a role in cancer development by means of polycomb-mediated transcriptional repression. [32] [33] [34] PcG target genes in human tumours, however, remain widely undiscovered and their utility in tumour prognosis unscrutinized. The PcG proteins BMI1, EZH2 and SUZ12 are frequently overexpressed in aggressive tumours including PCa. [17] [18] [35] [36] [37] The recent discovery of the BMI1 pathway and its downstream molecules indicates that gene expression signatures are associated with the stemness state of a cell. This has been shown to be a molecular predictor of cancer therapy outcome in prostate and breast cancers. 37 Therefore, in this study promoter methylation of three putative targets of the PcG protein/BMI1 driven pathway [20] [21] [22] [23] [24] [25] [26] [27] ARF has been observed earlier in various types of tumours, including melanoma, 38 squamous cell carcinoma of the skin, 39 colon cancer 28 and head and neck cancer, 40 among others. It depends on the tumour type as to which promoter at the CDKN2a locus is methylated more frequently, as methylation of both promoters is regulated separately. 41 CpG islands of both promoters in this locus lie 20 kb apart; a third closely related gene, p15 INK4b , is located further 14 kb upstream and also is methylated in different tumour types. 28, 41 Independent methylation of these two genes should not be surprising, as both gene products, p16
INK4a and p14 ARF , participate in different regulatory pathways to inhibit cell cycle progression. p16
INK4a inhibits the CyclinD/Cdk4/6 complex, whereas p14 ARF stabilizes p53 through sequestration of MDM2. 42 We hypothesize a yet unknown alternate mechanism other than the BMI1-driven pathway in the regulation of p16
INK4a and p14 ARF methylation in PCa. 43 
Methylation of p16
INK4a had no association with tumours with Gleason score 8 or more as it had in tumours with Gleason score 7. We attribute this to the low number of patients (n ¼ 10) in this group; many of them are pT3 tumours, Pn1 and 41 cm 3 . We are convinced that these results are not due to specific Although we found BMI-overexpression in more aggressive tumours with extraprostatic extension (pT3) and tumour size more than 1 cm 3 , there was no significant association between these variables and methylation of p16
INK4a and p14
